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ABSTRACT
Leprosy is an ancient disease which is caused due to bacterial infection while curable but endures to be a substantial health problem in numerous 
parts across the world. It is an extremely contagious disease that is caused by any of 3 strains of bacteria such as Mycobacterium tuberculosis; 
Nontuberculous Mycobacterium; and Mycobacterium leprae. In several regions of Brazil, leprosy is a health issue which is still an endemic. Mainly skin, 
peripheral nerves, eyes, and mucosa of the upper respiratory tract are affected due to this chronic infection. As per the data shared by WHO across 
159 countries globally, there were around 208,619 new leprosy cases reported. The global prevalence of leprosy is overcome with the aid of multidrug 
therapy which remains to be the chiefly targeted for treatment. The multidrug therapy gets attention as they show tremendous potential in fighting 
this disease. This review briefs about the different drugs and strategies which are used in treatment and superintendence of leprosy.
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INTRODUCTION
Mycobacteria are slow-growing immobile Gram-positive bacteria 
with rod-shaped characteristics and usually classified into three types 
such as Mycobacterium tuberculosis; Nontuberculous Mycobacterium; 
and Mycobacterium leprae [1-6]. The disease leprosy or Hansen’s 
disease which was discovered by Gerhard Henrik Armauer Hansen in 
1873 is an old and ancient curable bacterial causing disease caused 
by M. leprae bacillus (M. leprae). It produces chronic infection to 
humans and it mainly affects peripheral nervous systems and skin 
but may also get to sites such as eyes, mucus membrane, bone, testes 
along with many types of clinical phenotypes in the skin [7-10]. It is 
contagious and can be transmitted by coughs or even by contacting 
nasal fluids that are on the surface. Many reportedly observed that 
the human body can prevent infections but children are more at risk. 
Many countries such as India, Nepal, China, Japan, and Egypt have 
large numbers of leprosy infected patients. It is categorized into 
two types such as paucibacillary (PB) leprosy and multibacillary 
(MB) leprosy [11-18]. The initial one is characterized by one or a 
little hypo/hyperpigmented skin macules exhibiting loss of feeling 
(sensation, anesthesia) caused by inflammation of the peripheral 
nerve supply area. The second one is defined by generalized or diffuse 
skin involvement, peripheral nerve thickening under microscopic 
inspection, and has the potential to influence other organs, eyes, nose, 
testicles, and bone. The most advanced form of the disease is the 
nodular form of this condition. Other effects like multiple skin lesions 
without loss of sensation, plaques followed by dermis thickening as 
well as nasal congestion, and epistaxis are also associated with it. 
Here, we have summarized the characteristics differences between 
them in Table 1 [19-25].
PATHOGENESIS OF LEPROSY
The causative agent M. leprae is an acid-fast, Gram-positive obligate 
intracellular bacillus showing tropism in reticuloendothelial and 
peripheral system (especially Schwann cells) cells, The susceptible 
host will typically acquire species through the system or skin contact 
(between exudates of the skin lesions of a leprosy patient and 
another person’s abraded skin), Just a little proportion of infected 
individuals show symptoms of the disease with a period starting from 
6 months to 40 years or longer [26-30]. With its low pathogenicity 
condition, Bacilli migrate toward the neural tissue to the Schwann 
cells after entering the body. On the surface of Schwann cells, Toll-
like receptors (such as -1 and 2) also play a big role in triggering 
the genes of apoptosis and which boosts the onset of nerve damage 
found in mild disease [31-34]. Usually, Bacilli start multiplying slowly 
(about 12–14 days for one bacterium to divide into two) within the 
cells and get rid of damaged cells and invade other unaffected cells, 
Till this stage individual remains free from signs and symptoms of 
leprosy, as bacilli multiply, bacterial load increases within the body, 
and infection is detected by the immune system, lymphocytes and 
histiocytic (macrophages) invade the infected tissue. At this time, 
clinical manifestation may appear as the involvement of nerves with 
impairment of sensation and/or pad [35-40]. If it is not diagnosed 
and treated within the early stages, further progress of the diseases 
is decided by the strength of the patient’s immunologic response. 
Specific and effective cell-mediated immunity (CMI) provides 
protection and in this condition, it regulates the infection inside the 
body or generates leprosy PB type or if CMI is deficient then the 
disease spreads uncontrolled and produces MB leprosy with multiple 
system involvement. This may lead to invasion of the bloodstream 
which results in foci within the liver, spleen, adrenals, testicles, and 
bone marrow and excretion within the milk. In many reports, it was 
observed that lepromatous leprosy (MB leprosy) is more infectious 
than other types and has a poor prognosis [41-46]. The progress of 
the disease is also shown in Fig. 1.
The signs and symptoms for leprosy infection are moderate and slowly 
arising and are quite same to people that can present in syphilis, tetanus, 
and leptospirosis. The above are the primary symptoms of leprosy 
includes numbness, temperature as well as contact lost sensations, 
needles sensation, Ache (joint), deep pressure stimuli are weakened or 
missing, nerve injury, ulcers, rashes, lesions on skin (pigmented areas 
on the skin which result in losing the skin color), losing of eyebrows, 
disappearing of facial features, etc. [47-50].
TREATMENT AVAILABLE FOR LEPROSY
Antibiotics cure the bulk of cases of leprosy and the prescription 
of antibiotics with suitable dosage and period of administration 
depends upon the variety of the disease [51-55]. Mainly three drugs 
such as clofazimine (compound 1), rifampicin (compound 2), and 
dapsone (compound 3) are generally prescribed to treat leprosy 
infections [56-58]. Health practitioners typically prescribe antibiotics 
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for a minimum of 6–12 months or longer to treat the illness. Recently, the 
WHO has proposed that single-dose treatment of patients with only 1 
skin lesion with rifampicin, minocycline (Minocin), or ofloxacin (Floxin) 
is successful. Studies on other antibiotics are continuing [54,59-61]. 
Several medical practitioners have used steroid treatments to cut back 
discomfort and acute leprosy inflammation; however, clinical trials have 
found no clear long-term effects on nerve damage. The role of surgery 
within the treatment of leprosy exists after a patient has undergone 
medical therapy (antibiotics) with negative skin (no detectable acid-fast 
bacilli) and is typically required only in advanced cases [62-66]. The 
illness is treated with a mix of antibiotics like using the combination of 
rifampicin dapsone, and clofazimine to avoid the assembly of antibiotic 
resistance by bacteria, which could otherwise arise due to the amount 
of treatment. The disease treatment typically lasts between 1 and 2 
years. The condition will be reversed provided the therapy is done as 
specified. Apart from this many natural plant remedies are also available 
which include neem paste, hydrocotyle asiatica, and frankincense 
aromatherapy, respectively [67-74]. Patients should negotiate all home 
remedies with their practitioner before utilizing such methods.
Many reports suggested that the emergence of drug-resistant leprosy is a very 
critical situation in the successful treatment of leprosy infection. To tackle, 
this the research is ongoing to inhibit the enzyme ribonucleotide reductase 
(RNR) because of its involvement in the biosynthesis of nucleotides [49,75-
78]. Many reports also suggested that the enzyme dihydropteroate synthase 
(DHPS) is also one of the important enzymatic targets [79,80]. Hence, we 
thought to include the details of the agent developed for inhibiting the RNR 
and DHPS action. In the next section, we will discuss about those inhibitors 
and their structures as mentioned in Table 2.
In the year 2019, Ertas et al. reported the synthesis and evaluation of 
24 thiosemicarbazones derivatives against RNR enzyme. Their study 
results reported that two compounds (compound 4-5) have shown 
significantly better activity than reference compound metisazone. 
Further, their cytotoxic effects were also analyzed using MCF7 (human 
breast adenocarcinoma) and HEK293 (human embryonic kidney) cell 
lines, and these three compounds were shown a selective effect on the 
MCF7 and HEK293 cell lines, damaging and terminating more cancer 
cells than cisplatin as standard [81]. Misko and their group members have 
reported that enzyme RNR is one kind of essential anti-cancer target due 
to their involvement in the rate-limiting step of dNTP synthesis. They 
have further evaluated the class of naphthyl salicylic acyl hydrazone-
based inhibitor (NSAH) and reported that (compound 6) have shown 
significant inhibitory action against Panc1 carcinoma cell line with 
an IC50 of 0.393 mM through binding to the catalytic site. They have 
further modified the NSAH derivatives through incorporating cyclic 
and polar groups instead of naphthyl moiety that was found to occupy 
the phosphate-binding pocket within the C-site [82]. Crona et al. have 
evaluated the activity of anti-proliferative molecules for inhibiting the 
RNR catalyzed reduction of ribonucleotides to deoxyribonucleotides. 
Their study results concluded that NSC73735 (compound 7) can 
hinder the oligomerization of the RNR subunits of mammals as well as 
interruption of HL-60 cell culture in the cell cycle and can be used as a 
possible lead for further development [83]. Nasr et al. evaluated a series 
of acrylamide derivatives bearing the sulfasalazine moiety against 
Table 1: Difference between MB and paucibacillary
Characteristics PB MB leprosy
Skin lesions ● 1–5 lesions
● Asymmetrical




● No loss of sensation
Nerve lesions Only one nerve
Is involved
Two or more nerve are 
involved
PB: Paucibacillary, MB: Multibacillary
Fig. 1: Brief representation of leprosy pathogenesis
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DHPS. Their study results showed that two analogs (compound 8-9) 
have been shown significant action in opposition to Bacillus subtilis. 
Both compounds also displayed two and three folds the potency of 
amphotericin B against Syncephalastrum racemosum, respectively [84]. 
The earlier same group also reported that the anti-bacterial activity 
of 28 N-substituted sulfisoxazole analogs and reported that two 
compounds thiophene 10 and 6 thioglucosylpyridone 11 have shown 
significant inhibition of Escherichia coli and B. subtilis at IC50 value of 
0.007 µg/ml, respectively [85]. In the same year, almost eight pterin 
sulfonamide conjugates (general structure represented as compound 
12) were prepared and evaluated. All conjugates have been shown 
significant inhibition of DHPS competitively due to catalysis action of 
the present pyrophosphate group which is crucial to catalysis and is 
thought to market an ordering of the DHPS site [86].
CONCLUSION
M. leprae is the causative agent for leprosy infection. In the year 1981 
after the launching of multidrug therapy followed by the development 
of fixed duration therapy in the year 1992, revolutionized the treatment 
process. Many types of newly developed agents have been developed 
through showing inhibition of enzymes RNR and DHPS against leprosy 
infection. In the present review, the data related to those things are 
reported. This will help the readers in the successful development of 
new agents against bacterial infections.
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